FDA flubs off-label enforcement

When it comes to policing off-label marketing, the FDA is no SWAT team, a new report from the government's auditor shows. It's more like the Keystone Cops, ill-equipped to crack down even on blatant marketing abuses, the Associated Press reports. There's no staff exclusively assigned to monitor off-label marketing, and when the staff that monitors all prescription-drug advertising manages to catch a drugmaker promoting off-label uses, it takes an average of seven months for them to issue a warning--and an average of four more months for the company to fix the problem.

The agency tries to focus its attention on misrepresentations that could affect human health, the report found, but it lacks a system to track all the information it receives.

The General Accountability Office investigated off-label marketing enforcement at the request of Sen. Chuck Grassley, who, as you know, has been hounding drugmakers on various marketing-related issues all year. Whether the report will lead to any action--or just another set of hearings--remains to be seen.

- see the AP story

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.